Although dual checkpoint inhibition has been proven to be effective in multiple solid tumours19–22,27, further research is needed to evaluate how tumour biology, molecular heterogeneity, dynamics in tumour microenvironment and other patient factors may affect the efficacy of combined PD-L1 and CTLA-4 blockade. This evidence concerns the gene CD274 and neoplasm.